https://www.biospace.com/employer/3076212/genefab GeneFab en-US Thu, 10 Aug 2023 12:36:07 GMT https://www.biospace.com/genefab-launches-to-offer-innovative-manufacturing-and-synthetic-biology-design-services-for-a-broad-range-of-genetic-medicines GeneFab, LLC, a contract research, development and manufacturing organization partnering with the cell and gene therapy industry and backed by private equity firm Celadon Partners, LLC, announced a transaction with Senti Biosciences, Inc. in which GeneFab would sublease Senti Bio’s current good manufacturing practice facility, a portion of which is subject to certain conditions. Thu, 10 Aug 2023 12:36:07 GMT https://www.biospace.com/genefab-launches-to-offer-innovative-manufacturing-and-synthetic-biology-design-services-for-a-broad-range-of-genetic-medicines https://www.biospace.com/senti-bio-announces-second-quarter-2023-results-and-pipeline-updates Senti Biosciences, Inc., a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, reported financial results for the second quarter of 2023. Fri, 11 Aug 2023 12:36:13 GMT https://www.biospace.com/senti-bio-announces-second-quarter-2023-results-and-pipeline-updates https://www.biospace.com/senti-bio-announces-multiple-data-presentations-at-the-society-for-immunotherapy-of-cancer-2023-meeting Senti Biosciences, Inc. announced four poster presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting, being held November 1-5, 2023, in San Diego, CA. Wed, 27 Sep 2023 13:06:07 GMT https://www.biospace.com/senti-bio-announces-multiple-data-presentations-at-the-society-for-immunotherapy-of-cancer-2023-meeting https://www.biospace.com/senti-bio-announces-third-quarter-2023-results-and-pipeline-updates Senti Biosciences, Inc., a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, reported financial results for the third quarter of 2023. Mon, 13 Nov 2023 21:16:14 GMT https://www.biospace.com/senti-bio-announces-third-quarter-2023-results-and-pipeline-updates https://www.biospace.com/senti-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-reviews-recent-highlights Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter and full year ended December 31, 2023. Thu, 21 Mar 2024 19:06:10 GMT https://www.biospace.com/senti-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-reviews-recent-highlights https://www.biospace.com/genefab-announces-two-presentations-at-the-american-society-of-gene-and-cell-therapy-asgct-annual-meeting-2024 GeneFab, LLC (“GeneFab”), an expert contract research, development and manufacturing organization (CRDMO) today announced two poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, which will be held May 7 to 11, 2024 in Baltimore, MD. Mon, 22 Apr 2024 20:36:07 GMT https://www.biospace.com/genefab-announces-two-presentations-at-the-american-society-of-gene-and-cell-therapy-asgct-annual-meeting-2024 https://www.biospace.com/senti-bio-announces-first-quarter-2024-results-and-reviews-recent-corporate-highlights Senti Biosciences, Inc., a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, reported operational updates and financial results for the first quarter of 2024. Thu, 09 May 2024 20:06:14 GMT https://www.biospace.com/senti-bio-announces-first-quarter-2024-results-and-reviews-recent-corporate-highlights https://www.biospace.com/senti-bio-announces-first-patient-dosed-in-phase-1-clinical-trial-of-senti-202-for-the-treatment-of-relapsed-or-refractory-hematologic-malignancies-including-acute-myeloid-leukemia Senti Biosciences, Inc. today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (“AML”). Mon, 13 May 2024 12:16:04 GMT https://www.biospace.com/senti-bio-announces-first-patient-dosed-in-phase-1-clinical-trial-of-senti-202-for-the-treatment-of-relapsed-or-refractory-hematologic-malignancies-including-acute-myeloid-leukemia https://www.biospace.com/senti-bio-announces-second-quarter-2024-results-and-reviews-recent-corporate-and-pipeline-highlights Wed, 14 Aug 2024 01:33:37 GMT https://www.biospace.com/senti-bio-announces-second-quarter-2024-results-and-reviews-recent-corporate-and-pipeline-highlights https://www.biospace.com/press-releases/senti-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update Fri, 27 Mar 2026 13:16:42 GMT https://www.biospace.com/press-releases/senti-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update